-
1
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
DOI 10.1056/NEJMoa065044
-
RJ Motzer TE Hutson P Tomczak 2007 Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 115 124 (Pubitemid 46089672)
-
(2007)
New England Journal of Medicine
, vol.356
, Issue.2
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
Michaelson, D.4
Bukowski, R.M.5
Rixe, O.6
Oudard, S.7
Negrier, S.8
Szczylik, C.9
Kim, S.T.10
Chen, I.11
Bycott, P.W.12
Baum, C.M.13
Figlin, R.A.14
-
2
-
-
34249894171
-
Gastrointestinal perforation due to bevacizumab in colorectal cancer
-
DOI 10.1245/s10434-006-9337-9
-
MW Saif A Elfiky RR Salem 2007 Gastrointestinal perforation due to bevacizumab in colorectal cancer Ann Surg Oncol 14 1860 1869 (Pubitemid 46870935)
-
(2007)
Annals of Surgical Oncology
, vol.14
, Issue.6
, pp. 1860-1869
-
-
Saif, M.W.1
Elfiky, A.2
Salem, R.R.3
-
3
-
-
33750344419
-
Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy
-
2006 ASCO Annual Meeting Proceedings Part I
-
Sugrue M, Kozloff M, Hainsworth J et al (2006) Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 24:3535
-
(2006)
J Clin Oncol
, vol.24
, pp. 3535
-
-
Sugrue, M.1
Kozloff, M.2
Hainsworth, J.3
Al, E.4
-
4
-
-
36849056497
-
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
-
DOI 10.1200/JCO.2007.12.0782
-
SA Cannistra UA Matulonis RT Penson 2007 Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer J Clin Oncol 25 5180 5186 (Pubitemid 350232248)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.33
, pp. 5180-5186
-
-
Cannistra, S.A.1
Matulonis, U.A.2
Penson, R.T.3
Hambleton, J.4
Dupont, J.5
Mackey, H.6
Douglas, J.7
Burger, R.A.8
Armstrong, D.9
Wenham, R.10
McGuire, W.11
-
5
-
-
34447121952
-
Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab
-
DOI 10.1097/JTO.0b013e31805fea51, PII 0124389420070600000017
-
J Gray J Murren A Sharma 2007 Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab J Thorac Oncol 2 571 573 (Pubitemid 47171814)
-
(2007)
Journal of Thoracic Oncology
, vol.2
, Issue.6
, pp. 571-573
-
-
Gray, J.1
Murren, J.2
Sharma, A.3
Kelley, S.4
Detterbeck, F.5
Bepler, G.6
-
6
-
-
33644847440
-
Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
-
DOI 10.1200/JCO.2005.02.2194
-
S Faivre C Delbaldo K Vera 2006 Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 25 35 (Pubitemid 46630490)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.1
, pp. 25-35
-
-
Faivre, S.1
Delbaldo, C.2
Vera, K.3
Robert, C.4
Lozahic, S.5
Lassau, N.6
Bello, C.7
Deprimo, S.8
Brega, N.9
Massimini, G.10
Armand, J.-P.11
Scigalla, P.12
Raymond, E.13
-
7
-
-
33749505836
-
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
-
DOI 10.1016/S0140-6736(06)69446-4, PII S0140673606694464
-
GD Demetri AT van Oosterom CR Garrett 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 1329 1338 (Pubitemid 44528723)
-
(2006)
Lancet
, vol.368
, Issue.9544
, pp. 1329-1338
-
-
Demetri, G.D.1
Van Oosterom, A.T.2
Garrett, C.R.3
Blackstein, M.E.4
Shah, M.H.5
Verweij, J.6
McArthur, G.7
Judson, I.R.8
Heinrich, M.C.9
Morgan, J.A.10
Desai, J.11
Fletcher, C.D.12
George, S.13
Bello, C.L.14
Huang, X.15
Baum, C.M.16
Casali, P.G.17
-
8
-
-
34648873387
-
Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis
-
2007 ASCO Annual Meeting Proceedings Part I
-
Gore M, Porta C, Oudard S et al (2007) Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25:5010
-
(2007)
J Clin Oncol
, vol.25
, pp. 5010
-
-
Gore, M.1
Porta, C.2
Oudard, S.3
Al, E.4
-
9
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
DOI 10.1056/NEJMoa032691
-
H Hurwitz L Fehrenbacher W Novotny 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 (Pubitemid 38702844)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.23
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
Cartwright, T.4
Hainsworth, J.5
Heim, W.6
Berlin, J.7
Baron, A.8
Griffing, S.9
Holmgren, E.10
Ferrara, N.11
Fyfe, G.12
Rogers, B.13
Ross, R.14
Kabbinavar, F.15
-
10
-
-
42949149159
-
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study
-
LB Saltz S Clarke E Diaz-Rubio 2008 Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013 2019
-
(2008)
J Clin Oncol
, vol.26
, pp. 2013-2019
-
-
Saltz, L.B.1
Clarke, S.2
Diaz-Rubio, E.3
-
11
-
-
37849035249
-
Phase III clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and Princess Margaret Hospital phase II consortium
-
AA Garcia H Hirte F Fleming 2008 Phase III clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortium J Clin Oncol 26 76 82
-
(2008)
J Clin Oncol
, vol.26
, pp. 76-82
-
-
Garcia, A.A.1
Hirte, H.2
Fleming, F.3
-
12
-
-
36849019301
-
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A gynecologic oncology group study
-
RA Berger MW Sill BJ Monk 2007 Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study J Clin Oncol 25 5165 5177
-
(2007)
J Clin Oncol
, vol.25
, pp. 5165-5177
-
-
Berger, R.A.1
Sill, M.W.2
Monk, B.J.3
-
13
-
-
37549040613
-
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
-
K Miller M Wang J Gralow 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676
-
(2007)
N Engl J Med
, vol.357
, pp. 2666-2676
-
-
Miller, K.1
Wang, M.2
Gralow, J.3
-
14
-
-
33845490014
-
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
-
DOI 10.1056/NEJMoa061884
-
A Sandler R Gray MC Perry 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer N Engl J Med 355 2542 2550 (Pubitemid 44917502)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.24
, pp. 2542-2550
-
-
Sandler, A.1
Gray, R.2
Perry, M.C.3
Brahmer, J.4
Schiller, J.H.5
Dowlati, A.6
Lilenbaum, R.7
Johnson, D.H.8
-
16
-
-
38149117040
-
Pneumatosis intestinalis: A variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity
-
TR Asmis KY Chung JB Teitcher 2007 Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity Invest New Drugs 26 95 96
-
(2007)
Invest New Drugs
, vol.26
, pp. 95-96
-
-
Asmis, T.R.1
Chung, K.Y.2
Teitcher, J.B.3
|